reasanz
novartis europharm ltd - serelaxin - niewydolność serca - inne leki rozszerzające naczynia stosowane w leczeniu schorzeń kardiologicznych - leczenie ostrej niewydolności serca.
valdispert 125 mg tabletki drażowane
vemedia manufacturing b.v. - valerianae radicis extractum siccum + extractum nativum - tabletki drażowane - 125 mg
persen noc 445 mg tabletki drażowane
zentiva, k.s. - valerianae extractum hydroalcoholicum siccum - tabletki drażowane - 445 mg
candezek combi 8 mg + 5 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipini besilas - kapsułki twarde - 8 mg + 5 mg
candezek combi 8 mg + 10 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipini besilas - kapsułki twarde - 8 mg + 10 mg
candezek combi 16 mg + 10 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipinum - kapsułki twarde - 16 mg + 10 mg
candezek combi 16 mg + 5 mg kapsułki twarde
adamed pharma s.a. - candesartanum cilexetili + amlodipini besilas - kapsułki twarde - 16 mg + 5 mg
bimzelx
ucb pharma s.a. - bimekizumab - Łuszczyca - leki immunosupresyjne - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.